Human iPSC Derived Cardiomyocytes

Only %1 left

Catalog #

78529

As low as $610 *

Cat # Size Price*

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

Human iPSC Derived Cardiomyocytes are non-diseased, non-proliferative human cardiomyocytes differentiated from induced pluripotent stem cells (iPSC) using the small molecule Wnt-modulation strategy described by Lian et al.. The differentiated cells are functional, normal cardiomyocytes useful for in vitro modeling of cardiac biology and drug development studies.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

●

Product Data Gallery

Cardiac Troponin-T (cTNT) expression in Human iPSC Derived Cardiomyocytes by flow cytometry

Cardiac Troponin-T (cTNT) expression and localization in Human iPSC Derived Cardiomyocytes by immunofluorescence

Cell viability and plating efficiency of Human iPSC Derived Cardiomyocytes at thaw

Human iPSC Derived Cardiomyocytes response to the known cardiotoxic drug doxorubicin

Product Info

Storage and Usage

Citations

Host Cell Line

PBMC-derived, non-disease Human iPS Cell Line (XCells 30HU-002)

Supplied As

Each vial contains 1 or 5 million cells in 1 ml of STEMdiff Cardiomyocyte Freezing Media (Stem Cell Technologies #05030)

Materials Required But Not Supplied

Name	Ordering Information
Thaw Medium Kit C17	BPS Bioscience #78511
Maintenance Medium C17	BPS Bioscience #78509
Thiazovivin	BPS Bioscience #78506
DMEM/F12	ThermoFisher #11330032
Matrigel™	Corning #354230

Mycoplasma Testing

The cells have been screened to confirm the absence of Mycoplasma species.

Background

The discovery of the Yamanaka factors has enabled the reprogramming of mature human somatic cells to induced pluripotent stem cells with the ability to differentiate along the three germlines lineages involved in human development (endo-, meso- and ectoderm). The impact of this discovery has been most profound in research involving terminally differentiated, non-proliferating cell types which have traditionally been difficult to access.

One of the major causes of the death and burden on the health systems in the developed world are cardiovascular diseases. Human iPSC-derived cardiomyocytes have enhanced our understanding of human cardiac development, congenital heart diseases and mechanisms of drug-induced cardiotoxicity. In addition, the availability of human cardiac muscle cells can transform the drug discovery process. On the one hand, it allows high-throughput phenotypic screening of new drugs targeting cardiac disease. On the other hand, it allows cardiotoxicity studies to be performed very early on in the drug discovery without using more expensive, and ultimately less clinically relevant mouse models. These two aspects combined are expected to decrease the cost of drug development, since cardiac toxicity is a major cause of attrition in drug development pipelines. The ability to use a clinically relevant, amenable system to deepen our understanding of cardiac cell biology and drug responses can result in major benefits for the ageing population and economy of developed countries.

References

Takahashi K., et al., 2007, Cell 131: 861-872.
Yamanaka S., et al., 2012, Cell Stem Cell 10: 678-684.
Lian X., et al., 2012, PNAS 109(27): E1848-E1857.
Musunuru K., et al., 2018 Circulation: Genomic and Precision Medicine 11: e000043.
Mordwinkin., et al., 2013, Journal of Cardiovascular Translational Research 6: 22-30

Storage/Stability

Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at [email protected] if the cells are not frozen in dry ice upon arrival.

Growth Media

For best results, the use of validated and optimized media from BPS Bioscience is highly recommended. Other preparations or formulations of media may result in suboptimal performance. Cells should be maintained at 37°C with 5% CO₂.

Media Required for Cell Culture
Thaw Medium Kit C17 (BPS Bioscience #78511):
Component A: Maintenance Medium C17
Component B: 10% Serum Replacement
Component C: 10 mM Thiazovivin
Thaw Medium C17 Preparation (prepare immediately before use): add 5 ml of Component B and 50 µl of Component C to 45 ml of Component A in a sterile tissue culture hood. Do not filter.

Maintenance Medium C17 (BPS Bioscience #78509): RPMI 1640 medium supplemented with 5% B27 Supplement, 1% Penicillin/Streptomycin

Applications

Assess cardiotoxicity and phenotypic characteristics generated by drugs of interest.
Model human cardiac development.
Use as control in studies involving diseased or gene-edited cardiomyocytes

Shipping Temperature

-80°C

Notes

License Disclosure
Visit bpsbioscience.com/license for the label license and other key information about this product. The iPSC technology is protected by several patents, including US patent Nos. 8048999, 8058065, 8129187, 8278104, 8530238, 8900871, 9404124, 9499797, 10519425, and patent pending, for which iPS Academia Japan, Inc. has been granted license rights with a sub-licensable right. Commercial use of these cells is not allowed. Commercial use requires the appropriate license from iPS Academia Japan, Inc.

This cell line is for research use only, not for therapeutic or prophylactic use in humans or animals. Use in humans is strictly prohibited.

Publications using these cells should reference BPS Bioscience, Inc., San Diego.

Troubleshooting Guide
For further questions, please email [email protected].

Warnings

Avoid freeze/thaw cycles

Scientific Category

Cardiovascular

Regulatory Status

Research Use Only

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Human iPSC Derived Cardiomyocytes

PRODUCTS

SERVICES

RESOURCES

COMPANY